1 / 49

Postmarketing Drug Safety and Risk Intervention Studies

Postmarketing Drug Safety and Risk Intervention Studies. Evelyn M Rodriguez MD, MPH Director, DDREII, OPDRA. Topics for Today’s Discussion. Postmarketing Drug Safety Two Risk Intervention Case Studies Review of the Labeling History Study Objective, Methods, Results and Conclusions

tuan
Télécharger la présentation

Postmarketing Drug Safety and Risk Intervention Studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Postmarketing Drug Safety and Risk Intervention Studies Evelyn M Rodriguez MD, MPH Director, DDREII, OPDRA

  2. Topics for Today’s Discussion • Postmarketing Drug Safety • Two Risk Intervention Case Studies • Review of the Labeling History • Study Objective, Methods, Results and Conclusions • Summary / Considerations • Future Directions

  3. Why Post-Marketing Surveillance? • Limitations of Phase 3 Trials • Too few, too simple, too median aged, too narrow, too brief • Population of Users Expands After Drug Approval • Age, Sex, Race/Ethnicity, Use in pregnancy • Rare Events

  4. Postmarketing Safety Surveillance • Database reporting system: Adverse Event Reporting System (AERS) • Cost effective • Signal generation • Receives > 250,000 reports per year

  5. Postmarketing Causality Assessment • Temporal Relationship • Biological Plausibility • Known Class Effect • Previous Pre-marketing Findings • Dose-related Effect

  6. Postmarketing Causality Assessment • Onset Time and Progression • Confirmed Diagnosis • Dechallenge - discontinue drug • Rechallenge - restart drug • Underlying Disease • Concomitant Drugs

  7. Use of Cases Identified in AERS • Case definition - reporter’s clinical diagnosis or one from the literature • Develop Case Series • Causality Assessment • Conditions ofexposure • Risk Factors and Confounders

  8. Underreporting:Barriers to Reporting • Voluntary System • Recognize , Attribute , and Establish Adverse Event to Drug • Labeled adverse events less likely reported • Constraints, Litigation Fear, Desire to Publish Findings, Privacy Concerns

  9. Underreporting of Adverse Drug Reactions From the Literature

  10. Lotronex • Pre-marketing cases of ischemic colitis and constipation • Postmarketing reports of serious cases • Ischemic colitis • Serious complications of Constipation • Early in marketing (3 months)

  11. Possible Next Steps • Incidence Study for Serious Outcomes • Ischemic Colitis and Constipation difficult to ascertain in automated databases (ICD-9 codes and underreporting)

  12. Possible Next Steps • Risk Factor Study • Risk factor identification may be feasible for Ischemic Colitis IF complete ascertainment is assured • Constipation as a risk factor for serious GI outcomes hard to evaluate because it is associated with IBS, the indication for the drug

  13. Possible Next Steps • Implement Risk Interventions (e.g. Education, Labeling change) • Evaluate whether the Risk Interventions are achieving desired goals

  14. First Drug History Risk Intervention Study

  15. First Case History • Approved in January 1997 • Marketed in March 1997 • Seven months after marketing, first Acute Liver Failure death • Several Re-labelings and Dear Healthcare Practitioner letters including recommendations for Liver Transaminase (LT) testing

  16. Risk Intervention Study Objective • To assess the impact of the labeling changes regarding LT monitoring in a large managed care organization automated claims database using ICD-9 and CPT codes

  17. Risk Intervention Study Objective • Recommended LT monitoring varied slightly with each labeling change • Last labeling change recommended a baseline test with monthly monitoring for first 8 months, data presented to AC 3/99

  18. Overview of Study in the United HealthGroup Database Mar 97 25 Oct 97* 25 Oct 97 25 Oct 97 1 Dec 97 1 Dec 97 1 Dec 97* 30 Jun 98 30 Jun 98 30 Jun 98 1 Aug 98 1 Aug 98 1 Aug 98* 31 Dec 98 31 Dec 98 Cohort 1 n = 2307 Cohort 3 n = 1411 Cohort 3 n = 1411 Cohort 2 n = 2823

  19. LT Monitoring at Baseline after the First Prescription by Cohort

  20. Full Compliance with Monthly LT Monitoring by Cohort among Drug Users *Data Shown as Percentage of Eligible Subjects at Each Time Period

  21. Conclusion • Poor compliance with full LT monitoring scheme recommended by labeling • Better compliance with baseline LT testing that improved with each labeling change to a maximum of 45%

  22. FDA Dave Graham MD, MPH Evelyn M Rodriguez MD, MPH FDA Cooperative Agreement Program UHG Carol Drinkard, PhD Deborah Shatin, PhD Investigators

  23. Second Drug History Risk Intervention Study

  24. Second Drug History • Approved in July 1993 • First reports of Ventricular Arrhythmia with an antifungal drug 12/94 • Multiple Dear Healthcare Practitioner letters that described new contraindications and warnings for specific drugs and conditions

  25. Second Drug History • Black Box Warning with Contraindication for QT interval prolonging drugs and Cardiovascular and Medical Conditions, 2nd line indication & DHPL 6/98

  26. Study Objective • To describe the impact of the labeling changes through 6/98 • CYP P450 3A4 Enzyme Inhibitor Drugs • QT Prolonging Drugs • Contraindicated Comorbidities

  27. Automated Databases: Sites A, B, and C Time Periods Before DHPL: 7/97 - 6/98 After DHPL: 7/98 - 6/99 Methods

  28. Study Sites N based on calendar 1998; no material change for any of databases in 1999.

  29. Cohorts Before and After Labeling Changes through 6/98

  30. Results: Contraindicated Drug or Disease

  31. Conclusion • No reduction in contraindicated use was found following labeling changes and DHPL of 6/98

  32. Study Group • FDA Investigators • Diane Wysowski Ph.D., Evelyn M. Rodriguez, Dave Graham M.D., M.P.H. • United Health Group (Site A) • Deborah Shatin, Ph.D., Stephanie D. Schech, Ph.D. • Tennessee Medicaid (Site B) • Walter Smalley, M.D., M.P.H., Jim Daugherty, M.S., Wayne Ray, Ph.D. • Harvard Consortium (Site C) • Jerry Gurwitz, M.D, Susan Andrade, D.Sc., Jackie Cernieux, M.P.H. (Meyers Primary Care Institute, Fallon Healthcare System); Richard Platt, M.D., M.S., Arnold Chan, M.D., Dr.P.H. (Harvard Pilgrim Healthcare, Michael Goodman, Ph.D. (HealthPartners)

  33. Summary / Considerations • Risk Intervention studies are useful to assess the effect of labeling and DHPL • These two studies suggest labeling fatigue phenomenon • Other strategies, such as Education targeting Prescribers and Patients, may be useful to encourage the implementation of recommended risk management efforts

  34. Future Directions • Determine • How prescribers interpret information from DHPL & other educational materials • Best format to inform prescribers and patients of drug safety concerns -- PPI, Med Guide, company sales materials, CME courses

  35. Future Directions • Determine • How information, contraindications, and monitoring recommendations are used • Feasibility of constipation as contraindication

  36. Future Directions • Conduct risk intervention studies in multiple databases that reflect the range of health care services delivery systems • Validate the findings in databases with medical record review

  37. Back Up Slides

  38. Sample Size of Study Population, UHG Ever received drug 9,369 Total person-years 4,873  90 day prior enrollment 7,568 Included in LT monitoring study 6,541

  39. Criteria for Inclusion in the Study Cohort for LT Monitoring • Enrollment Date  90 days prior to 1st troglitazone prescription

  40. Study Method for Measuring Liver Transaminase Monitoring in UHG Baseline Month 1 Month 2 -30d - + 7d +/- 7d +/- 7d …….. Last Rx. -30d 1st Rx. 30d 60d

  41. Cohorts

  42. Age Distribution (%) of Cisapride Users, Pre Year % Female: Site A: 60.3 Site B: 67.2 Site C: 62.8 %

  43. Contraindicated Drugs (At least 1 day of use concurrent with cisapride use) Antiarrhythmics: procainamide, quinadine, sotalol, amiodarone, disopyramide Antipsychotics: chlorpromazine, mesoridazine, thioridazine, trifluoperazine, thiothixene, haloperidol, fluphenazine, triflupromazine, pimozide, risperidone, perphenazine Cyclic antidepressants: amitriptyline, clomipramine, imipramine, doxepin, trimiprramine, amoxapine, desipramine, nortriptyline, protiptyline, maprotiline

  44. Contra-indicated Drugs

  45. Heart Failure Other Ischemic Heart Disease Electrolyte Disorder Ventricular Arrhythmia Renal Failure Respiratory Failure Contraindicated Comorbidity Any diagnosis in the 180 days preceding t0. Restricted to cohort members with 180+ days prior enrollment

  46. Contraindicated Comorbidity Based on (pre/post) persons with 180+ days of enrollment: Site A: 13613/12418; B: 4379/4229; C: 6848/5812

  47. Contraindicated Drug or Comorbidity, By Age Site B only

  48. Future Directions • Conduct studies among prescribers to identify the “best communication practices” that will enhance timely and useful communication by industry and FDA • Assess the impact of the health care services delivery system on prescribing and medical practice in the context of safer drug use

  49. Future Directions • Form industry-government partnerships & interagency collaborations to conduct further studies to identify effective risk intervention strategies • Using the results from these studies, implement strategies and evaluate success

More Related